About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Global Biomarkers Market Size, Share, and Forecast 2030
Biomarkers Market

Biomarkers Market Size, Share & Trends Analysis Report By Type (Safety, Efficacy, Validation), By Application (Diagnostics, Drug Discovery & Development, Personalized Medicine, Others), By Disease (Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRPH2473DR
Last Updated : September 05, 2022
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Biomarkers Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Safety
        1. By Value
      3. Efficacy
        1. By Value
      4. Validation
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Diagnostics
        1. By Value
      3. Drug Discovery & Development
        1. By Value
      4. Personalized Medicine
        1. By Value
      5. Others
        1. By Value
    4. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Neurological Diseases
        1. By Value
      5. Immunological Diseases
        1. By Value
      6. Others
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Safety
        1. By Value
      3. Efficacy
        1. By Value
      4. Validation
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Diagnostics
        1. By Value
      3. Drug Discovery & Development
        1. By Value
      4. Personalized Medicine
        1. By Value
      5. Others
        1. By Value
    4. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Neurological Diseases
        1. By Value
      5. Immunological Diseases
        1. By Value
      6. Others
        1. By Value
    5. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Safety
          1. By Value
        3. Efficacy
          1. By Value
        4. Validation
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Diagnostics
          1. By Value
        3. Drug Discovery & Development
          1. By Value
        4. Personalized Medicine
          1. By Value
        5. Others
          1. By Value
      3. By Disease
        1. Introduction
          1. Disease By Value
        2. Cancer
          1. By Value
        3. Cardiovascular Diseases
          1. By Value
        4. Neurological Diseases
          1. By Value
        5. Immunological Diseases
          1. By Value
        6. Others
          1. By Value
    6. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Safety
        1. By Value
      3. Efficacy
        1. By Value
      4. Validation
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Diagnostics
        1. By Value
      3. Drug Discovery & Development
        1. By Value
      4. Personalized Medicine
        1. By Value
      5. Others
        1. By Value
    4. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Neurological Diseases
        1. By Value
      5. Immunological Diseases
        1. By Value
      6. Others
        1. By Value
    5. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Safety
          1. By Value
        3. Efficacy
          1. By Value
        4. Validation
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Diagnostics
          1. By Value
        3. Drug Discovery & Development
          1. By Value
        4. Personalized Medicine
          1. By Value
        5. Others
          1. By Value
      3. By Disease
        1. Introduction
          1. Disease By Value
        2. Cancer
          1. By Value
        3. Cardiovascular Diseases
          1. By Value
        4. Neurological Diseases
          1. By Value
        5. Immunological Diseases
          1. By Value
        6. Others
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Safety
        1. By Value
      3. Efficacy
        1. By Value
      4. Validation
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Diagnostics
        1. By Value
      3. Drug Discovery & Development
        1. By Value
      4. Personalized Medicine
        1. By Value
      5. Others
        1. By Value
    4. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Neurological Diseases
        1. By Value
      5. Immunological Diseases
        1. By Value
      6. Others
        1. By Value
    5. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Safety
          1. By Value
        3. Efficacy
          1. By Value
        4. Validation
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Diagnostics
          1. By Value
        3. Drug Discovery & Development
          1. By Value
        4. Personalized Medicine
          1. By Value
        5. Others
          1. By Value
      3. By Disease
        1. Introduction
          1. Disease By Value
        2. Cancer
          1. By Value
        3. Cardiovascular Diseases
          1. By Value
        4. Neurological Diseases
          1. By Value
        5. Immunological Diseases
          1. By Value
        6. Others
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Safety
        1. By Value
      3. Efficacy
        1. By Value
      4. Validation
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Diagnostics
        1. By Value
      3. Drug Discovery & Development
        1. By Value
      4. Personalized Medicine
        1. By Value
      5. Others
        1. By Value
    4. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Neurological Diseases
        1. By Value
      5. Immunological Diseases
        1. By Value
      6. Others
        1. By Value
    5. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Safety
          1. By Value
        3. Efficacy
          1. By Value
        4. Validation
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Diagnostics
          1. By Value
        3. Drug Discovery & Development
          1. By Value
        4. Personalized Medicine
          1. By Value
        5. Others
          1. By Value
      3. By Disease
        1. Introduction
          1. Disease By Value
        2. Cancer
          1. By Value
        3. Cardiovascular Diseases
          1. By Value
        4. Neurological Diseases
          1. By Value
        5. Immunological Diseases
          1. By Value
        6. Others
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Safety
        1. By Value
      3. Efficacy
        1. By Value
      4. Validation
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Diagnostics
        1. By Value
      3. Drug Discovery & Development
        1. By Value
      4. Personalized Medicine
        1. By Value
      5. Others
        1. By Value
    4. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Neurological Diseases
        1. By Value
      5. Immunological Diseases
        1. By Value
      6. Others
        1. By Value
    5. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Safety
          1. By Value
        3. Efficacy
          1. By Value
        4. Validation
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Diagnostics
          1. By Value
        3. Drug Discovery & Development
          1. By Value
        4. Personalized Medicine
          1. By Value
        5. Others
          1. By Value
      3. By Disease
        1. Introduction
          1. Disease By Value
        2. Cancer
          1. By Value
        3. Cardiovascular Diseases
          1. By Value
        4. Neurological Diseases
          1. By Value
        5. Immunological Diseases
          1. By Value
        6. Others
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Biomarkers Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. F. Hoffmann-La Roche Ltd.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Abbott Laboratories
    3. Epigenetics AG
    4. General Electric
    5. Johnson & Johnson Services, Inc.
    6. Thermo Fisher Scientific, Inc.
    7. Bio-Rad Laboratories, Inc.
    8. Siemens Healthineers AG
    9. Qiagen
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global biomaterials market size was valued at USD 106.51 billion in 2022. It is estimated to reach USD 619.27 billion by 2031, growing at a CAGR of 15.8% during the forecast period (2023–2031). A biomaterial is a substance design
Buy Now
Global Report
The global cancer biomarker market size was valued at USD 15.86 billion in 2023. It is estimated to reach USD 55.57 billion by 2032, growing at a CAGR of 14.95% during the forecast period (2024–2032). The global cancer biomarker market is prima
Buy Now
Global Report
The global cardiac biomarkers market size was valued at USD 14.73 billion in 2022. It is estimated to reach USD 48.66 billion by 2031, growing at a CAGR of 14.2% during the forecast period (2023–2031). Cardiac biomarkers are substances th
Buy Now
Global Report
Digital Biomarkers Market Size The global digital biomarkers market size was valued at USD 3.43 billion in 2023 and is projected to reach USD 49.17 billion by 2032, growing at a CAGR of 34.43% during the forecast period (2024–2032). In recent years,
Buy Now
Global Report
The global renal biomarkers market size was valued at USD 1,119.82 million in 2022. It is estimated to reach USD 2,158.11 million by 2031, growing at a CAGR of 7.56% during the forecast period (2023–2031). Biomarkers are substances that c
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.